Biocidal products falling under the scope of BPR require an authorisation to be granted before they can be placed on the market. The regulation establishes a two-stage system for the registration of biocidal products, involving:
- Active Substance Approval: any active substance contained in a biocidal product must first have been approved at an EU-wide level for use in the appropriate product type.
- Biocidal Product Authorisation: when an active substance has been approved for the relevant product type, a biocidal product containing the active substance must receive an authorisation for use in the Member State where it will be placed on the market.
The registration processes involve rigorous assessment of both active substances and biocidal products by regulators to ensure adequate protection of human and animal health, and the environment. Products must also demonstrate to be sufficiently effective for their intended use and according to any label claims made. The process places obligations on applicants to supply comprehensive technical dossiers detailing information on the intrinsic properties, hazards, efficacy and intended use patterns of the biocidal product. Exposure and emission scenario assessments must also be performed to demonstrate that no unacceptable risk to human and animal health or the environment will result from the intended uses of the product.